CN101366922B - Proprietary Chinese medicine for treating empyrosis - Google Patents
Proprietary Chinese medicine for treating empyrosis Download PDFInfo
- Publication number
- CN101366922B CN101366922B CN 200810022935 CN200810022935A CN101366922B CN 101366922 B CN101366922 B CN 101366922B CN 200810022935 CN200810022935 CN 200810022935 CN 200810022935 A CN200810022935 A CN 200810022935A CN 101366922 B CN101366922 B CN 101366922B
- Authority
- CN
- China
- Prior art keywords
- tincture
- rhizoma
- cortex phellodendri
- litre
- gram
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 229940098465 tincture Drugs 0.000 claims abstract description 27
- 206010053615 Thermal burn Diseases 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 238000002156 mixing Methods 0.000 claims abstract description 16
- 235000002991 Coptis groenlandica Nutrition 0.000 claims abstract description 15
- 244000247747 Coptis groenlandica Species 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 13
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims abstract description 12
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 6
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 6
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims abstract description 6
- 235000019341 magnesium sulphate Nutrition 0.000 claims abstract description 6
- 239000011593 sulfur Substances 0.000 claims abstract description 6
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 6
- 239000007787 solid Substances 0.000 claims description 10
- 240000007817 Olea europaea Species 0.000 claims description 5
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- -1 Calamina Chemical compound 0.000 claims description 2
- 238000002481 ethanol extraction Methods 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 11
- 239000000463 material Substances 0.000 abstract description 3
- 229940126589 solid medicine Drugs 0.000 abstract 2
- HSTZMXCBWJGKHG-UHFFFAOYSA-N (E)-piceid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-UHFFFAOYSA-N 0.000 abstract 1
- 241001313857 Bletilla striata Species 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 229940105847 calamine Drugs 0.000 abstract 1
- 239000010440 gypsum Substances 0.000 abstract 1
- 229910052602 gypsum Inorganic materials 0.000 abstract 1
- 229910052864 hemimorphite Inorganic materials 0.000 abstract 1
- 210000003487 olivary nucleus Anatomy 0.000 abstract 1
- 229960003764 polydatin Drugs 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 238000002791 soaking Methods 0.000 abstract 1
- 235000001508 sulfur Nutrition 0.000 abstract 1
- HSTZMXCBWJGKHG-CUYWLFDKSA-N trans-piceid Polymers O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-CUYWLFDKSA-N 0.000 abstract 1
- 235000014692 zinc oxide Nutrition 0.000 abstract 1
- 239000011787 zinc oxide Substances 0.000 abstract 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 abstract 1
- 231100000241 scar Toxicity 0.000 description 8
- 206010052428 Wound Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 206010020718 hyperplasia Diseases 0.000 description 7
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- BTLXPCBPYBNQNR-UHFFFAOYSA-N 1-hydroxyanthraquinone Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2O BTLXPCBPYBNQNR-UHFFFAOYSA-N 0.000 description 2
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 2
- 239000010282 Emodin Substances 0.000 description 2
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 2
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 2
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 2
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 2
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000863032 Trieres Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000008738 huangbai Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 1
- OISYIJRGMYJBRH-UHFFFAOYSA-N physcione Natural products COc1cc(O)c2C(=O)c3ccc(O)cc3C(=O)c2c1 OISYIJRGMYJBRH-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Abstract
The invention discloses an external Chinese patent medicine for treating burn and scald. The external Chinese patent medicine is formed by mixing mixed tincture and solid medicine powder. The mixed tincture comprises the following compositions in soaking concentration (the weight of the composition/the volume of ethanol): 150 to 300 gram/litre of polydatin, 150 to 250 gram/litre of olivary nucleus lotus, 180 to 280 gram/litre of bletilla striata, 40 to 75 gram/litre of burnet and 100 to 150 gram/litre of rhubarb; coptis tincture with concentration of between 150 and 250 percent (the weight of the composition/the volume of ethanol) is added into the mixed tincture; and solid medicine powders of gypsum, calamine, sulfur and magnesium sulfate in enough amount are taken out and mixed in the mixed tincture. Compared with the prior art, the external Chinese patent medicine obviously reduces the treatment course of three-degree burn and scald and the cicatricial proliferation rate in particular, has wide material source and low price, does not need operation and skin-grafting, has low treatment expenses for patients and relieves the economic burden of the patients.
Description
Technical field
The present invention relates to a kind of Chinese patent medicine for the treatment of burn and scald.
Background technology
The applicant is in the patent of ZL94100404.X in the patent No. of application on January 19th, 94, a kind of Chinese patent medicine for the treatment of burn and scald is disclosed, finding after for many years clinically use has very significantly curative effect to the treatment of II degree and the following burn and scald of II degree, but also there are some problems in the impaired therapeutic effect of III degree burn and scald skin, it is longer to be mainly reflected in the course for the treatment of, practice finds that the time of this technical scheme treatment III degree burn and scald skin is 6-7 week, and the scar hyperplasia rate is more than 60%.
Summary of the invention
The technical problem to be solved in the present invention is, improves on the basis of patent ZL94100404.X, shortens the course for the treatment of that the treatment burn and scald is especially treated III degree burn and scald, reduces the scar hyperplasia rate.
The present invention realizes that the scheme of technique effect is such: a kind of Exterior-applied Chinese patent medicine for the treatment of burn and scald, mainly comprise and use the solid medicated powder that is mixed by the Rhizoma Polygoni Cuspidati of ethanol extraction, olive nuclear lotus, the Pseudobulbus Bletillae (Rhizoma Bletillae), Radix Sanguisorbae, the prepared mixing tincture of Radix Et Rhizoma Rhei and Gypsum Fibrosum, Calamina, sulfur, magnesium sulfate, the shared solid medicated powder of each composition overall weight percent is in the solid medicated powder: Gypsum Fibrosum 18-38%, Calamina 15-25%, sulfur 10-25%, magnesium sulfate 30-50% is characterized in that every liter of mixing tincture ingredient amount is equivalent to following crude drug amount:
Rhizoma Polygoni Cuspidati 150---300g olive nuclear lotus 150---250g
The Pseudobulbus Bletillae (Rhizoma Bletillae) 180---280g Radix Sanguisorbae 40---75g
Radix Et Rhizoma Rhei 100---150g.
Solid medicated powder and mixing tincture fully are mixed into moistening hybrid medicine, and mixing the tincture consumption can be enough to make mixing tincture medicine moistening.
Better for the sterilization granulation promoting effect that makes this medicine, in mixing tincture, add the Cortex Phellodendri tinctura coptis that contains Cortex Phellodendri and Rhizoma Coptidis composition, this kind Cortex Phellodendri tinctura coptis and the weight ratio=1.0-2.0 that mixes tincture: 1.5-2.5;
The ingredient amount is equivalent to following crude drug amount in every liter of the described Cortex Phellodendri tinctura coptis:
Rhizoma Coptidis 120---180g Cortex Phellodendri 80---140g.
More than mix tincture and the employed alcohol concentration of tinctura coptis and be generally 65% (V/V), the traditional Chinese medicinal material raw materials that uses does not have special requirement.
The present invention is the tissues such as the collagen fiber of regulating burn and scald skin inflammatory cell, stem cell on the basis of former patent of invention ZL94100404.X, in mixing tincture, increase the use of Radix Et Rhizoma Rhei, strengthen the consumption of the Pseudobulbus Bletillae (Rhizoma Bletillae), thereby in tinctura coptis, added in addition the purpose that the extensive pedigree antibiotics such as Rhizoma Coptidis, Cortex Phellodendri reach Shorten the Treatment Process, improve recovery rate.
Increase the composition of Radix Et Rhizoma Rhei, consumption its objective is mediator's internal milieu, promote hematoblastic adhesion and aggregation capability, increase platelet count and fibrin collagen content, it is active to reduce Antithrombin III, make collagenocyte generate as early as possible collagen fiber, thereby reach the purpose of wound surface normal healing.The main chemical compositions of Radix Et Rhizoma Rhei is the derivant of hydroxyanthraquinone, can suppress non-specific immunity.Radix Et Rhizoma Rhei also contains the effective ingredient such as aloe-emodin, chrysophanol, emodin, chrysophanic acid, physcione, rhatannin in addition; Aloe-emodin, emodin, chrysophanic acid have antibacterial action, anti-bacteria nucleic acid and protein synthesis, anti-bacteria biological oxidation enzyme system, inducement interferon.The main component of the Pseudobulbus Bletillae (Rhizoma Bletillae) is 60% Pseudobulbus Bletillae (Rhizoma Bletillae) colloid and a certain amount of starch, the wet goods that volatilizees, its Main Function hemostasis, detumescence, granulation promoting.The sepage of III degree burn and scald is more, and the acidity of the acid compared with normal body fluid of this sepage is strong; How fever, inflammation, sepage all can cause the molten quantity not sufficient of human body blood, destroy the balance of inside and outside environment.The present invention increases the consumption that uses Radix Et Rhizoma Rhei, strengthens the Pseudobulbus Bletillae (Rhizoma Bletillae), with mixes tincture in other components compatibility coordination, the treatment of the above burn and scald of III degree is had obvious curative effect.
The extensive pedigree antibiotic such as Rhizoma Coptidis, Cortex Phellodendri can be resisted staphylococcus aureus, streptococcic infection, and the present invention uses Rhizoma Coptidis and Cortex Phellodendri to make tinctura coptis, coordinates with mixing the tincture compatibility, can antibioticly protect from infection, and impels the normal healing of burn wound surface.
The present invention can also keep the disclosed technical scheme of ZL94100404.X, such as the Rhizoma Zingiberis Recens powder accelerating for the speed of impelling the muscle self-sow, can add to account for solid medicated powder gross weight 5-15% etc.The technical scheme of not stating among the present invention can be identical with disclosed technical scheme among the ZL94100404.X.
Using method of the present invention is: the use initial stage is applied to affected part wrapping with ointment once a day, wound surface convergence without sepage after, per two days are once, and ointment is applied to the affected part wrapping.
The present invention compares with prior art, shows through the many cases result in clinical application, the treatment of II and the above burn and scald of III degree has been obtained very significantly improved, and has reached and has shortened the course for the treatment of, has reduced the scar hyperplasia rate, alleviates the purpose of patient's misery; Particularly concerning the above burn and scald of III degree, use medicine of the present invention as long as about 5 weeks, the scar hyperplasia rate obviously reduces from using to foreshorten in former medicine 6-7 week, the Chinese medicine wide material sources are cheap in addition, do not perform the operation, do not make skin graft, treatment cost is lower, has alleviated patient's financial burden.
The specific embodiment
The present invention is described in detail below in conjunction with embodiment.
At first produce control sample: the prescription of control sample is: Rhizoma Polygoni Cuspidati 500g, and olive nuclear lotus 450g, Pseudobulbus Bletillae (Rhizoma Bletillae) 500g, Radix Sanguisorbae 125g,
Getting above-mentioned various former medicine all shreds in 2L ethanol (65v/v) to soak and got filtrate in 72 hours and must mix tincture, gained mixing tincture is mixed with the 1.5L tinctura coptis, and tinctura coptis is that 400g chopping Rhizoma Coptidis is soaked 72 hours filtration gained in 2L ethanol (65v/v);
Get Gypsum Fibrosum 300g, Calamina 200g, sulfur 160g, magnesium sulfate 360g, behind the abundant mix homogeneously of pulverize, getting q.s is blended in the mixing tincture, after making it fully moistening, add mixing tincture and the melt liquid paraffin of solid medicated powder gross weight 8% and the vaseline of 15-25% and fully stir, it is stand-by to make it be paste dosage-form.
Table 1 is four kinds of prescriptions of the present invention:
Medicine name embodiment 1 embodiment 2 embodiment 3 embodiment 4
Mix tincture Pseudobulbus Bletillae (Rhizoma Bletillae) 360g 420g 500g 560g
Radix Et Rhizoma Rhei 200g 240g 280g 300g
The Cortex Phellodendri Rhizoma Coptidis
Cortex Phellodendri 200g 250g
Tincture
The manufacture method of HUANGBAI(sic) tinctura coptis is: Cortex Phellodendri and the Rhizoma Coptidis of chopping are positioned over immersion filtration in 72 hours gained in the 2L ethanol (65v/v);
Other composition, the Rhizoma Coptidis composition in the Cortex Phellodendri tinctura coptis, solid medicated powder, paraffin and the vaseline that mix in the tincture in the above Example formulations are equal identical with control sample, and preparation method is also identical.
Therapeutic Method:
The burn and scald initial stage, the patient of group on probation is applied to the affected part wrapping with ointment, use once every day, after 10 days, used once clinic trial 1 year in per two days, the track record result of use, crowd on probation is all the patient of different parts, the uniform III degree of age distribution burn and scald, and about about 15%, the result is as follows greatly for the trier III degree burn and scald area of track record:
Control sample embodiment 1 embodiment 2 embodiment 3 embodiment 4
Wound healing
45 days 32 days 32 days 33 days 30 days
Average time
7 people's sepages, 6 people, 11 people's sepages, 7 people, 10 people's sepages
Time remaining sepage time time remaining sepage time time remaining
7-8 days, continue 7-8 4-5 days,, continue 7-8 4-5 days, its
All the other people of symptom are to the sky, and all the other all the other people are the sky extremely, all the other remaining people to 10
Hurted sb.'s feelings in 10 days wound people to 10 day 7-8 days to 10 everyday wound receive
Convergence, minute wound are closed up and are restrained, wound convergence, secretion
Secretion reduces holds back, and secretion secretions subtracts to be held back, and secretions reduces
Thing reduces few thing and reduces
Middle severe scar
Trace hypertrophy people 13 people 6 people 9 people 7 people 9 people
Number
Test number 16 people 12 people 19 people 13 people 17 people
By upper use record as can be known, below 5 weeks, patient's restore cycle obviously shortens in the wound healing healing time, and the scar hyperplasia rate obviously reduces.
With embodiment 1 treatment I-II burn and scald patient, be applied to affected part wrapping with ointment every day, cured in 3-5 days, and the scar hyperplasia rate is 1-3%, and with the embodiment 1 dark II burn and scald patient for the treatment of, be applied to affected part wrapping with ointment every day, cured in 7-14 days, and the scar hyperplasia rate is 3-4%.
Through clinical use checking, without obvious ill symptoms, the burn and scald pain alleviates very fast the patient in the process of using medicine of the present invention, and the skin physiological function was recovered in 1 year afterwards substantially.
The present invention can use without prejudice to the concrete form of spirit of the present invention or principal character and summarize.Above-mentioned embodiment only is can not limit the present invention to explanation of the present invention, and therefore, the implication suitable with claims of the present invention and any change in the scope all should be thought to be included in the scope of claims.
Claims (1)
1. Exterior-applied Chinese patent medicine for the treatment of burn and scald, Rhizoma Polygoni Cuspidati, olive nuclear lotus, Pseudobulbus Bletillae (Rhizoma Bletillae), Radix Sanguisorbae, the prepared mixing tincture of Radix Et Rhizoma Rhei by ethanol extraction, contain the Cortex Phellodendri tinctura coptis of Cortex Phellodendri and Rhizoma Coptidis composition, the solid medicated powder that Gypsum Fibrosum, Calamina, sulfur, magnesium sulfate mix forms, and it is characterized in that:
The shared solid medicated powder of each composition overall weight percent is in the described solid medicated powder: Gypsum Fibrosum 18-38%, Calamina 15-25%, sulfur 10-25%, magnesium sulfate 30-50%;
Every liter of ingredient amount of described mixing tincture is equivalent to following crude drug amount:
Rhizoma Polygoni Cuspidati 150---300g olive nuclear lotus 150---250g
Pseudobulbus Bletillae (Rhizoma Bletillae) 180---280g Radix Sanguisorbae 40---75g
Radix Et Rhizoma Rhei 100---150g;
In mixing tincture, add described Cortex Phellodendri tinctura coptis, Cortex Phellodendri tinctura coptis and the weight ratio of mixing tincture=(1.0-2.0): (1.5-2.5);
The ingredient amount is equivalent to following crude drug amount in every liter of the described Cortex Phellodendri tinctura coptis:
Rhizoma Coptidis 120---180g Cortex Phellodendri 80---140g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810022935 CN101366922B (en) | 2008-07-02 | 2008-07-02 | Proprietary Chinese medicine for treating empyrosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810022935 CN101366922B (en) | 2008-07-02 | 2008-07-02 | Proprietary Chinese medicine for treating empyrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101366922A CN101366922A (en) | 2009-02-18 |
| CN101366922B true CN101366922B (en) | 2013-04-10 |
Family
ID=40411014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200810022935 Active CN101366922B (en) | 2008-07-02 | 2008-07-02 | Proprietary Chinese medicine for treating empyrosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101366922B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940671A (en) * | 2015-06-01 | 2015-09-30 | 张颖慧 | Nursing external application traditional Chinese medicinal ointment for treating burns |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1107046A (en) * | 1994-01-19 | 1995-08-23 | 俞初忠 | Chinese proprietary medicine for curing scalding |
-
2008
- 2008-07-02 CN CN 200810022935 patent/CN101366922B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1107046A (en) * | 1994-01-19 | 1995-08-23 | 俞初忠 | Chinese proprietary medicine for curing scalding |
Non-Patent Citations (2)
| Title |
|---|
| 南京中医药大学."大黄、白及".《中药大辞典第2版上册》.上海科学技术出版社,2006,第140、141、143、940页. |
| 李厚宽."治烧烫伤验方".《四川中医》.1988,(第5期),第27页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101366922A (en) | 2009-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Neuman et al. | In vitro anti-inflammatory effects of hyaluronic acid in ethanol-induced damage in skin cells | |
| Aljady et al. | Biochemical study on the efficacy of Malaysian honey on inflicted wounds: an animal model | |
| CN103272153B (en) | Antibacterial gel and preparation method thereof | |
| CN102139033B (en) | Chinese medicinal composition for treating skin wound of pregnant woman after cesarean section | |
| CN101496839B (en) | Chinese medicine compound and preparation method thereof | |
| CN101366922B (en) | Proprietary Chinese medicine for treating empyrosis | |
| CN1824081A (en) | External use preparation for treating vulnus slow agglutination and its preparation method | |
| CN102652763A (en) | Traditional Chinese medicine preparation for treating burn and scald and preparation method thereof | |
| DE60010886T2 (en) | EXTRACTS, FORMULATION AND USE OF MEDICAMENTS FROM LEAVES OF CAJANUS CAJAN (L.) MILSP. | |
| CN102028875B (en) | Medicament for treating open wound and preparation method thereof | |
| CN114652748A (en) | Preparation method and application of medical gynecological lotion containing stem cell bacteriostatic factors | |
| CN101152290B (en) | Externally used powder preparation stypticum | |
| CN103381196A (en) | Composition used for treating cervical erosion and application thereof | |
| CN109793757B (en) | Composition for inhibiting growth of skin scar and preparation method and application thereof | |
| CN107823442B (en) | Hemostatic and anti-infectious pharmaceutical composition | |
| CN1084196C (en) | Burn ointment | |
| CN103655771B (en) | Treat Chinese medicine preparation of skin ulcer and preparation method thereof | |
| CN109646512B (en) | A topical Chinese medicinal composition for promoting healing of chronic intractable wound | |
| CN102485260A (en) | Ointment composed of radix astragali and garden burnet | |
| CN1181267A (en) | Medicine for treating impetigo | |
| CN1051003C (en) | Chinese proprietary medicine for curing scalding | |
| CN102327371A (en) | Nano silver-zinc-selenium element Chinese medicinal negative ion far infrared ointment for externally treating burns and scalds | |
| CN115006474B (en) | Traditional Chinese medicine compatibility antibacterial drug | |
| CN106266152A (en) | A kind of pharmaceutical composition treating eczema and its production and use | |
| CN106822223A (en) | A kind of astragalus polyose Radix Angelicae Sinensis polysaccharide composition iron supplementary and preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Yu Chuzhong Document name: Notification of Decision on Request for Restoration of Right Addressee: Yu Chuzhong Document name: Notification of Passing Examination on Formalities |
|
| DD01 | Delivery of document by public notice |
Addressee: Yu Chuzhong Document name: Review of business letter |
|
| DD01 | Delivery of document by public notice |
Addressee: Yu Chuzhong Document name: Notification to Pay the Fees Addressee: Yu Chuzhong Document name: Review of business letter |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Yu Chuzhong Document name: payment instructions |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Yu Chuzhong Document name: payment instructions |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Yu Chuzhong Document name: Notice of Termination of Patent Rights |